Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 16, 2014, 40 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $45.75 to $7,830,985.00.

Highlighted Stocks Traded by Insiders:

Acuity Brands (AYI) - FREE Research Report

Hance James H Jr, who is Director at Acuity Brands, bought 8,000 shares at $122.94 on Oct. 16, 2014. Following this transaction, the Director owned 8,165 shares meaning that the stake was boosted by 4848.48% with the 8,000-share transaction.

The shares most recently traded at $129.40, up $6.46, or 4.99% since the insider transaction. Historical insider transactions for Acuity Brands go as follows:

  • 4-Week # shares sold: 927
  • 12-Week # shares sold: 927
  • 24-Week # shares sold: 927

The average volume for Acuity Brands has been 373,900 shares per day over the past 30 days. Acuity Brands has a market cap of $5.4 billion and is part of the technology sector and electronics industry. Shares are up 15.92% year-to-date as of the close of trading on Thursday.

Acuity Brands, Inc. designs, produces, and distributes lighting solutions, components, and services for commercial, institutional, industrial, infrastructure, and residential applications in North America and internationally. The stock currently has a dividend yield of 0.42%. The company has a P/E ratio of 32.5. Currently, there are 4 analysts who rate Acuity Brands a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AYI - FREE

TheStreet Quant Ratings rates Acuity Brands as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Acuity Brands Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Medidata Solutions (MDSO) - FREE Research Report

De Vries Glen Michael, who is President at Medidata Solutions, sold 20,000 shares at $40.29 on Oct. 16, 2014. Following this transaction, the President owned 911,894 shares meaning that the stake was reduced by 2.15% with the 20,000-share transaction.

The shares most recently traded at $41.39, up $1.10, or 2.65% since the insider transaction. Historical insider transactions for Medidata Solutions go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 158,456
  • 24-Week # shares sold: 278,456

The average volume for Medidata Solutions has been 503,200 shares per day over the past 30 days. Medidata Solutions has a market cap of $2.2 billion and is part of the technology sector and computer software & services industry. Shares are down 32.51% year-to-date as of the close of trading on Thursday.

Medidata Solutions, Inc. provides cloud-based clinical development solutions for life sciences in the United States and internationally. The company has a P/E ratio of 340.7. Currently, there are 10 analysts who rate Medidata Solutions a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDSO - FREE

TheStreet Quant Ratings rates Medidata Solutions as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and premium valuation. Get the full Medidata Solutions Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Cozadd Bruce C, who is Chairman and CEO at Jazz Pharmaceuticals, sold 5,000 shares at $142.77 on Oct. 16, 2014. Following this transaction, the Chairman and CEO owned 569,023 shares meaning that the stake was reduced by 0.87% with the 5,000-share transaction.

The shares most recently traded at $153.06, up $10.29, or 6.72% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 51,000
  • 12-Week # shares sold: 123,927
  • 24-Week # shares sold: 198,593

The average volume for Jazz Pharmaceuticals has been 919,900 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $8.8 billion and is part of the health care sector and drugs industry. Shares are up 15.61% year-to-date as of the close of trading on Thursday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 113.4. Currently, there are 10 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null